Last Price$4.3(4.0%)
Market Cap$211.4B
(1,274.8%)
Industry median - (123.1%)
5Y Historical average - (984.4%)
N/A
Industry median - (129.8%)
5Y Historical average - N/A
(61.9%)
Industry median - (51.8%)
5Y Historical average - 368.0%
(31.7%)
Industry median - (51.0%)
5Y Historical average - (49.9%)
SLN Capital Allocation Rating
SLN Capital Allocation rating
4.4
SLN Capital Allocation rating performance
SLN Capital Allocation metrics
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Competing with SLN Capital Allocation
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Capital Allocation score | ROIC | ROIC - WACC | CROIC | ROE | ROCE | Shares count growth | Shareholder yield |
$211.4B | 4.4 | (1,274.8%) | N/A | (1,093.2%) | (61.9%) | (31.7%) | 25.3% | 0.0% | |
$402.0B | 6.1 | 35.5% | 28.0% | 24.3% | 76.5% | 46.8% | (1.0%) | 2.2% | |
$125.5B | 4.8 | (15.0%) | (22.6%) | (11.5%) | (3.3%) | (5.5%) | 0.1% | 1.3% | |
$74.0B | 6.2 | 25.0% | 17.4% | 24.6% | 13.7% | 10.3% | 1.4% | 4.3% | |
$38.1B | 4.2 | (41.3%) | N/A | (24.0%) | (4.8%) | (8.5%) | 2.2% | 0.0% | |
$31.3B | 3.9 | (7.2%) | (14.8%) | (4.0%) | (559.4%) | (2.6%) | 2.4% | 0.0% | |
$27.1B | 5.2 | (41.4%) | (48.4%) | 37.5% | (1.7%) | (5.5%) | (0.8%) | 0.0% | |
$14.8B | 4.9 | (12.7%) | (20.5%) | 13.4% | 1.0% | (6.1%) | (14.1%) | 13.6% | |
$14.6B | 4.5 | (3,335.4%) | (3,343.2%) | (2,216.2%) | (53.5%) | (51.1%) | 3.6% | 0.0% | |
$14.0B | 7.3 | 65.4% | 57.7% | 68.4% | 19.1% | 16.0% | (5.1%) | 7.2% | |
$1,846.9M | 4.3 | (38.4%) | (45.1%) | (41.5%) | (25.3%) | (24.7%) | 0.0% | 0.0% |
FAQ
What is the Silence Therapeutics plc (SLN) ROIC (Return on Invested Capital)?
The Silence Therapeutics plc (SLN) ROIC is (1,274.8%), compared to the industry median of ((123.1%)) and the 5-year historical average of (984.4%).
What is the Silence Therapeutics plc (SLN) ROIC minus WACC (Weighted Average Cost of Capital)?
The Silence Therapeutics plc (SLN) ROIC minus WACC is N/A, compared to the industry median of ((129.8%)) and the 5-year historical average of N/A.
What is the Silence Therapeutics plc (SLN) ROE (Return on Equity)?
The Silence Therapeutics plc (SLN) ROE is (61.9%), compared to the industry median of ((51.8%)) and the 5-year historical average of 368.0%.
What is the Silence Therapeutics plc (SLN) ROCE (Return on Capital Employed)?
The Silence Therapeutics plc (SLN) ROCE is (31.7%), compared to the industry median of ((51.0%)) and the 5-year historical average of (49.9%).